Ezetimibe
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Ezetimibe lowers LDL-C about 15-20% by blocking intestinal cholesterol absorption.
Ezetimibe has no CYP3A4 metabolism and a cleaner muscle/metabolic profile than statins, but pregnancy, severe hepatic impairment, cyclosporine, bile acid sequestrants, and gallbladder-risk combinations still matter.
Ezetimibe lowers LDL-C about 15-20% by blocking intestinal cholesterol absorption. It is mainly lipid infrastructure: useful alone when statins are not tolerated, and stronger as an add-on to statins or PED-era lipid control.
Main watch items are GI discomfort, rare headache or fatigue, pregnancy avoidance, severe hepatic impairment, cyclosporine exposure, bile acid sequestrant timing, and gallbladder-risk combinations.
Low-burden LDL support with outcome evidence when added to simvastatin in IMPROVE-IT, plus little CYP3A4 overlap and no statin-like muscle signal in the article evidence.
High for its lane: a consistent 15-20% LDL reduction is realistic, with stronger effects when paired with statins or broader cardiometabolic changes.
Do not combine with cyclosporine without dose reduction — cyclosporine markedly increases ezetimibe plasma levels.
Intro
Ezetimibe is a cholesterol absorption inhibitor approved in 2002 as the first drug to specifically block intestinal cholesterol uptake rather than hepatic synthesis.
Unlike statins, which work in the liver by inhibiting HMG-CoA reductase, ezetimibe works at the brush border of the jejunum — blocking the NPC1L1 (Niemann-Pick C1-Like 1) transporter that shuttles both dietary and biliary cholesterol into enterocytes. The result is a 15-20% reduction in LDL-C from baseline, achieved without touching the cytochrome P450 system, without depleting CoQ10, and without a statin-like myopathy signal.
The IMPROVE-IT trial (2015) established ezetimibe's hard cardiovascular outcome evidence in combination therapy: in 18,144 post-ACS patients followed for 7 years, adding ezetimibe to simvastatin reduced the primary composite endpoint (CV death, MI, stroke, rehospitalization, revascularization) from 34.7% to 32.7% — a statistically significant absolute risk reduction of 2%, HR 0.936. This resolved a decade of controversy around whether adding non-statin LDL lowering to statin therapy can translate to outcome benefit.
In the performance community, ezetimibe occupies a unique position: it can layer into AAS protocols without CYP3A4 drug-drug interactions and without adding the muscle-symptom concern that makes statins harder for some heavily training users. The standard pairing is ezetimibe 10mg + pitavastatin 1-4mg — pitavastatin covers hepatic synthesis suppression, ezetimibe covers absorption blockade. Together, they address both cholesterol production and absorption pathways while remaining compatible with common oral-androgen planning.
For natural athletes and longevity-focused users, ezetimibe is often the absorption-blockade pillar in a broader cardiometabolic stack. Its low performance burden, fixed dosing, and outcome-backed combination data make it a common first pharmacologic LDL-management step before escalating to more expensive or injectable agents.
Observed Effects
LDL-C reduction is the primary and most reliable effect: monotherapy reduces LDL by 15-20% from baseline across multiple RCTs and meta-analyses.
In the community, one practitioner detailed a case where ezetimibe 10mg was predicted to reduce LDL from 95 to 70-75 mg/dL — a 15-20% absolute reduction, matching the clinical data. In the real-world first-person account from Dad Strength Daily, LDL dropped from 131 to 72 mg/dL on GLP-1 plus ezetimibe over one year.
As a statin add-on, ezetimibe provides an additional 15-20% LDL reduction beyond the statin alone, enabling aggressive LDL targets (below 70 mg/dL) that statin monotherapy alone cannot reach in many patients. This is the mechanism behind IMPROVE-IT's success: average LDL in the combination arm fell below 53 mg/dL vs 69 mg/dL in the statin-alone arm.
ApoB management: while trials focus on LDL-C, the LDL-reducing mechanism operates at the ApoB particle level — fewer cholesterol-loaded LDL particles are synthesized when hepatic cholesterol delivery falls. ApoB reduction tracks proportionally with LDL-C reduction.
Anti-inflammatory effects beyond LDL: ezetimibe suppresses the NLRP3 inflammasome, reduces CRP, and lowers systemic inflammation markers. Community practitioners explicitly note that ezetimibe 'lowers systemic inflammation' as an advantage for AAS users who carry elevated inflammatory burden. This pleiotropic benefit may explain why IMPROVE-IT results exceeded purely LDL-mediated predictions.
Triglycerides and HDL: modest TG reduction (~8%), minimal HDL effect. For AAS users where HDL is suppressed 50% by androgen use, ezetimibe will not restore HDL — this is not its mechanism, and community practitioners explicitly acknowledge LDL management as the priority because HDL is not controllable during cycles.
Field Reports
First-person experience data across multiple accounts paints a consistent picture: ezetimibe is well-tolerated, effective, and unnoticed in daily life for most users.
The clearest n=1 lipid outcome in the available evidence is LDL 131→72 mg/dL over a year on GLP-1 + ezetimibe, with no side effects reported. Because GLP-1 therapy was running at the same time, this should be read as combination-context evidence rather than a clean ezetimibe monotherapy result.
Biohacker-style logs tend to pair ezetimibe with lipid panels, visceral-fat tracking, CRP, and weight trends rather than subjective performance notes. That matches the drug's real-world role: the benefit is mostly visible in labs, not in a feeling during training.
FH patient accounts show the standard clinical escalation pattern: ezetimibe added to rosuvastatin when statin monotherapy leaves LDL insufficiently controlled. In that context, ezetimibe bridges the gap between statin monotherapy and injectable PCSK9 therapy for some patients.
Patient communities also document the tolerability split: most users tolerate it well, while a minority report GI effects such as bloating, gas, abdominal pain, or diarrhea. Rare outliers report headaches, fatigue, or brain-fog-like symptoms. Those reports do not overturn the clinical safety profile, but they keep the article honest: a small fraction of users will not tolerate ezetimibe.
Community Consensus
Ezetimibe's adoption in performance communities followed a straightforward logic: enhanced athletes care about bloodwork, and AAS can push lipid panels in the wrong direction — HDL down, LDL and ApoB up.
The statin-as-default solution brings its own friction for some users: concern about muscle symptoms, training fatigue, and interaction complexity in already crowded stacks. Ezetimibe offered a cleaner absorption-blockade lane: different mechanism, no CYP overlap, and no statin-like muscle signal.
The community consensus is practical rather than glamorous: ezetimibe works predictably for LDL, does not feel like a performance drug, and is most useful when bloodwork shows the need. This positions it as cycle-support infrastructure alongside liver, blood-pressure, and kidney-risk tools — harm reduction without an obvious performance cost.
Practitioner-style community guidance is usually favorable but bounded: ezetimibe is often treated as one of the easiest lipid drugs to tolerate, while aggressive LDL/ApoB targets for enhanced athletes usually require the paired synthesis-suppression lane rather than ezetimibe alone.
For natural athletes in contest prep, ezetimibe is sometimes framed as dietary flexibility — the ability to eat more eggs and meat without the same dietary-cholesterol penalty. That is not a license to ignore saturated fat or ApoB; it is a practical reason some athletes prefer ezetimibe over more restrictive diet-only lipid management.
The longevity community treats ezetimibe as the absorption-blockade pillar in evidence-based cardiovascular risk reduction, usually beside a statin or statin-free synthesis inhibitor rather than as a standalone aging intervention.
Risks & Monitoring
The safety profile of ezetimibe is the most clinically favorable of any cholesterol-lowering drug class.
The BMJ Medicine 2022 systematic review and meta-analysis (RCTs + cohort studies) found no significant increase in myopathy/rhabdomyolysis, LFT elevation, cancer, new-onset diabetes, or musculoskeletal events compared to placebo.
GI effects are the most commonly reported real-world adverse experiences: abdominal pain, bloating, gas, and diarrhea. These occur in a minority of patients (estimated 2-5%) and are dose-independent (no dose other than 10mg exists). Dietary modification — reducing high-fat meals that stimulate cholesterol-rich bile secretion — may reduce symptom severity. One patient in the BHF community accepted the GI discomfort because of demonstrated LDL efficacy.
Rare adverse events (documented in patient report databases, not in RCTs at statistically significant rates): headache, brain fog, exhaustion, joint pain. One Drugs.com reviewer reported headaches severe enough to require frequent ibuprofen and led to discontinuation. Another patient initially attributed brain fog and exhaustion to atorvastatin but reported partial recurrence on ezetimibe alone — a minority experience.
No myopathy risk: ezetimibe does not inhibit HMG-CoA reductase, does not deplete CoQ10, does not cause mitochondrial dysfunction in skeletal muscle. Multiple studies in statin-intolerant patients (including those with statin-induced myopathy) show zero muscle symptom recurrence with ezetimibe monotherapy. For performance athletes, this is the key safety distinction.
No hepatotoxicity: no CYP450 metabolism means no hepatic CYP load. No LFT elevations attributable to ezetimibe alone have been documented in RCTs. When dual statin+ezetimibe therapy produces LFT elevation, the statin is the responsible agent — as illustrated by the waymorethanweightloss.com case where a patient on atorvastatin+ezetimibe had LFT 69 (ULN=40); the statin was correctly identified as the cause.
No new-onset diabetes: unlike statins, ezetimibe has no documented association with insulin resistance or new-onset T2D. This is especially relevant for AAS users where insulin sensitivity is already challenged by androgenic signaling.
No statin-associated cognitive effects: statins carry a known brain fog risk (particularly lipophilic statins that cross the blood-brain barrier). Ezetimibe does not cross into the CNS and has no documented cognitive effects.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish LDL-C baseline before initiating and track response to therapy. Target LDL <70 mg/dL for high-risk patients and AAS users; <100 mg/dL for general prevention.
ApoB better reflects true atherosclerotic particle burden than LDL-C alone. Important for AAS users where particle count can remain elevated even when LDL-C appears acceptable.
Confirm liver baseline before initiating, especially when combining with hepatically-metabolized drugs (statins, oral androgens). Ezetimibe itself does not cause LFT elevation, but serves as baseline for combination monitoring.
Tracks anti-inflammatory effect beyond LDL reduction. Relevant for AAS users where elevated inflammation drives plaque progression independent of LDL. Ezetimibe reduces hsCRP; monitoring confirms the pleiotropic benefit.
Assess LDL response at 4-8 weeks after initiation. Guides whether statin add-on or dose escalation of the pair (pitavastatin) is needed to reach target LDL <70 mg/dL.
Avoid With
Do not combine Ezetimibe with the following. Sorted highest-severity first.
Why:Cyclosporine inhibits ezetimibe glucuronide clearance, markedly increasing ezetimibe AUC. May lead to excessive LDL reduction and potential adverse effects.
What to do:Use ezetimibe with caution and at reduced monitoring frequency if cyclosporine is co-prescribed. This combination is rare in performance contexts but relevant for transplant patients.
Why:Bile acid sequestrants bind cholesterol in the GI tract and can reduce ezetimibe bioavailability by preventing its absorption and enterohepatic recycling.
What to do:If co-prescribing, take ezetimibe at least 2 hours before or 4 hours after the bile acid sequestrant.
Why:Fibrates increase biliary cholesterol secretion; ezetimibe blocks its reabsorption. In gallbladder disease, the resulting cholesterol-rich bile may increase gallstone risk.
What to do:No pharmacokinetic interaction, but clinical monitoring for cholecystitis/cholelithiasis is warranted in susceptible individuals.
Why:No direct pharmacokinetic interaction — ezetimibe does not use CYP450 pathways shared with 17-aa androgens. The note is clinical: if LFT elevation occurs on dual ezetimibe + oral androgen therapy, the androgen is the suspected culprit, not ezetimibe. Monitor LFT at baseline and mid-cycle.
What to do:Ezetimibe is safer with oral androgens than statins. The interaction note is for clinical attribution of LFT elevation, not for contraindication.
Protocols By Goal
AAS cycle support (LDL management): Ezetimibe 10mg + Pitavastatin 1-4mg daily. Target LDL <70 mg/dL. No CYP3A4 interaction with oral androgens. Monitor lipid panel at baseline, 4-6 weeks into cycle, and 4-8 weeks post-PCT.
Longevity and primary cardiovascular prevention: Rosuvastatin 10mg + Ezetimibe 10mg as the core lipid pair, with optional telmisartan + empagliflozin when blood pressure, renal, glucose, or broader cardiometabolic risk justifies the added drugs. Target LDL <70 mg/dL and ApoB <80 mg/dL in high-risk prevention contexts.
Statin-intolerant patients: Ezetimibe 10mg monotherapy as primary LDL intervention. Reduces LDL 15-20%. If insufficient, consider bempedoic acid + ezetimibe (Nexlizet) — bempedoic acid is a hepatic cholesterol synthesis inhibitor that, unlike statins, requires activation only in the liver (not in muscle), thus avoiding statin myopathy.
High-LDL on optimized statin: Add ezetimibe 10mg as the first intensification step. Expected additional LDL reduction: 15-20% beyond statin alone. Do this before escalating to PCSK9 inhibitor.
Familial hypercholesterolemia (FH): Ezetimibe + high-intensity statin combination is standard of care. Target LDL <100 mg/dL (or <70 mg/dL if ASCVD present). FH patients often require all three classes (statin + ezetimibe + PCSK9i) for adequate control.
Dosing Details
Single approved dose: 10mg once daily. No food requirement. No timing restriction. No loading protocol.
For AAS cycle support: begin ezetimibe 10mg daily at cycle initiation. Continue throughout the cycle and through PCT until lipid panels normalize (typically 4-8 weeks post-cycle). Common pairing: pitavastatin 1-4mg + ezetimibe 10mg — both taken daily regardless of oral androgen scheduling.
For general cardiovascular prevention: 10mg once daily, indefinitely. If LDL target not achieved with ezetimibe monotherapy, add rosuvastatin 5-10mg (the Attia cardiometabolic protocol). If LDL still above target, escalate rosuvastatin dose or consider PCSK9 inhibitor.
Community LDL target context: for AAS users, the practitioner-recommended target is LDL 70-75 mg/dL given the elevated inflammatory and ApoB burden from androgenic use. This is below the general population threshold of <100 mg/dL for primary prevention. Achieving <70 mg/dL often requires the combination of ezetimibe + pitavastatin.
Monitoring cadence: baseline lipid panel, then recheck at 4-8 weeks after initiation. Annual panels for stable patients on continuous therapy.
Stacks & Alternatives
Preferred AAS cycle support pair — covers hepatic synthesis suppression without CYP3A4 interaction; ezetimibe covers absorption blockade. Together achieve dual-pathway LDL reduction compatible with oral androgens.
Attia Cardiometabolic Core pair for longevity users; rosuvastatin covers hepatic synthesis, ezetimibe covers absorption; does not cross blood-brain barrier.
Broader cardiometabolic stack — adds ARB and SGLT2i for blood-pressure, renal, and glucose-risk coverage alongside the lipid management pair.
Metabolic and lipid management combination; GLP-1 improves insulin sensitivity and promotes weight loss while ezetimibe addresses LDL independently. Real-world case: LDL 131→72 on this combination.
Anti-inflammatory cardiorenal protocol for AAS users — both reduce systemic inflammation; empagliflozin provides SGLT2-mediated kidney protection for androgenically-stressed users.
Alternatives
Stack Cost
Low stack tax for most users: ezetimibe is oral, fixed-dose, non-suppressive, non-CYP, and mostly adds lipid-monitoring discipline rather than endocrine, liver, CNS, or injection burden.
The article frames ezetimibe as an LDL/ApoB management tool with no myopathy, no CYP450 metabolism, and no LFT signal as monotherapy. The main tax is verifying whether the expected 15-20% LDL-C reduction is enough or whether a statin, bempedoic acid, or PCSK9 path is needed.
The article identifies a hard cyclosporine interaction, timing separation with bile acid sequestrants, and gallbladder caution with fibrates. It otherwise emphasizes no CYP3A4 overlap, which makes the interaction burden lower than statins in androgen-heavy stacks.
Baseline and follow-up fasting lipid panel are required, ApoB is recommended, and CMP is mainly contextual when ezetimibe is paired with statins or oral androgens. This is a modest lab burden compared with compounds that require endocrine recovery, injection surveillance, or organ-toxicity tracking.
Women can use the same fixed dose, and there is no virilization or HPG suppression, but the article explicitly marks pregnancy as contraindicated because fetal sterol supply depends on cholesterol biology.
Generic access is cheap and widely available, with fixed 10 mg dosing. Access and quality risk are much lower than peptide or injectable-gray-market compounds, though prescription status still matters in the US.
- ·Do not combine with cyclosporine without prescriber-level monitoring and dose/context review; the article flags this as the main hard interaction.
- ·If using cholestyramine, colesevelam, or another bile acid sequestrant, separate ezetimibe dosing by the timing rule in the article so absorption is not blunted.
- ·In users with gallbladder disease, treat fibrate co-use as a caution lane and monitor for cholelithiasis or cholecystitis symptoms.
- ·For AAS cycle support, do not assume ezetimibe alone solves androgen-driven dyslipidemia; recheck lipids at 4-8 weeks and add the statin/synthesis-suppression lane if LDL or ApoB remains above target.
- ·Discontinue before attempting pregnancy and avoid during pregnancy or lactation unless a clinician has a compelling indication.
- ·Creates a lipid-monitoring lane: baseline fasting lipid panel, repeat at 4-8 weeks, and ApoB when the user is targeting aggressive cardiovascular-risk reduction.
- ·In AAS stacks, it may create a paired pitavastatin or rosuvastatin decision if LDL/ApoB remain above the article's target range.
- ·In longevity stacks, it fits as the absorption-blockade pillar beside statin, telmisartan, and SGLT2/GLP-1 metabolic tools rather than replacing those tools.
The article describes a single fixed 10 mg daily dose, no titration, no performance impairment, no HPG suppression, and a straightforward lipid-panel feedback loop.
- ·The user is pregnant, trying to conceive, or lactating
- ·The user is on cyclosporine or complex transplant/immunosuppressive therapy
- ·The user has familial hypercholesterolemia, post-ACS disease, or LDL/ApoB targets that require specialist cardiovascular management
No suppression, no taper, no receptor rebound, and no injection logistics are described. The main consequence of stopping is LDL drifting back toward baseline as intestinal cholesterol absorption resumes.
- ·LDL-C and ApoB may rise back toward pre-treatment baseline
- ·Users relying on ezetimibe for AAS-cycle lipid support may lose their main LDL-control lane if they stop before post-cycle normalization
Treat ezetimibe as the absorption lane, not the whole lipid plan; add or adjust a statin, bempedoic acid, or specialist lipid therapy when labs show the target is missed.
Confirm adherence and timing, reduce high-fat meal triggers if relevant, and discontinue or switch strategy if symptoms persist.
Review medication list before starting; apply the separation rule for sequestrants and escalate cyclosporine or gallbladder-risk cases to clinician management.
Stop and route to clinician guidance; the article marks pregnancy as contraindicated because cholesterol handling is relevant to fetal development.
The article explicitly contraindicates pregnancy because fetal development depends on cholesterol biology.
The article identifies cyclosporine as the hard interaction because it markedly increases ezetimibe exposure.
The article says ezetimibe is not recommended in severe hepatic impairment even though monotherapy is not framed as hepatotoxic.
The article flags a cholelithiasis/cholecystitis caution when fibrates and altered biliary cholesterol handling overlap.
Practical Setup
Dietary interaction: take with or without food — no pharmacokinetic food interaction. However, a clinically useful framing is that ezetimibe blocks dietary cholesterol, so pairing it with a diet that limits saturated fat and dietary cholesterol amplifies the LDL benefit. Existing article evidence identifies saturated fat restriction and dietary cholesterol restriction as synergistic with ezetimibe.
Egg and meat flexibility: because ezetimibe blocks dietary cholesterol absorption, some community practitioners allow more dietary cholesterol flexibility while on ezetimibe — particularly eggs, which are protein-dense for athletes. This is a conditional flexibility claim, not permission to ignore saturated fat, ApoB, or follow-up labs.
Limitation — incomplete absorption block: NPC1L1 inhibition is not 100% complete. Some dietary cholesterol still enters, and the hepatic compensatory synthesis response (SREBP-2 upregulation of HMG-CoA reductase) partially offsets the absorption reduction. This is why ezetimibe monotherapy has a ceiling effect at ~20% LDL reduction, and why adding a statin (which directly suppresses the compensatory synthesis) is additive rather than redundant.
Drug interactions requiring attention: cyclosporine (markedly increases ezetimibe levels), bile acid sequestrants (reduce ezetimibe bioavailability), fibrates in gallbladder disease (cholelithiasis risk). No CYP3A4 interactions — this is the key clinical and community advantage.
Hepatic impairment: not recommended in severe hepatic impairment (Child-Pugh C). Mild-moderate impairment: no dose adjustment needed. Ezetimibe monotherapy is not framed here as hepatotoxic; if LFT elevation occurs in a combined regimen with a statin or oral androgen, investigate the co-medication first.
Pregnancy: avoid during pregnancy and discontinue before attempting pregnancy. Cholesterol is required for fetal development, and ezetimibe's LDL-lowering mechanism could interfere with fetal sterol supply.
Cost and access: generic ezetimibe ~$15-40/month US. OTC in some jurisdictions. Gray-market availability for performance community. Nexlizet (bempedoic acid + ezetimibe) is a fixed-dose combination for statin-intolerant patients — requires prescription, costs more, but useful when both mechanisms are desired in a statin-free protocol.
Mechanism Deep Dive
NPC1L1 inhibition is the primary mechanism. The Niemann-Pick C1-Like 1 protein is a multi-pass membrane transporter expressed on the apical surface of jejunal enterocytes and on hepatocanalicular membranes.
NPC1L1 transports unesterified cholesterol and plant sterols from the intestinal lumen into enterocytes, where cholesterol is packaged into chylomicrons and delivered to the lymphatic system and ultimately the portal vein.
Ezetimibe binds NPC1L1 directly, inducing endocytosis of the transporter complex, removing it from the brush border membrane. This blocks cholesterol uptake from both dietary sources and from biliary recirculation. Biliary cholesterol contributes a substantial portion of the total intestinal cholesterol load — the liver secretes cholesterol-rich bile into the duodenum, and without NPC1L1 function, this biliary cholesterol pool passes through the intestine unabsorbed. This is why ezetimibe works even on low-cholesterol diets.
Downstream hepatic response: reduced cholesterol delivery from the portal vein → decreased hepatic intracellular cholesterol → SREBP-2 activation → upregulation of both LDL receptors (LDL-R) and HMG-CoA reductase. The LDL-R upregulation clears more circulating LDL particles, producing the net LDL-C reduction. The HMG-CoA reductase upregulation is a partial compensatory synthesis response that limits the LDL reduction to ~15-20% (explaining why statin co-administration, which directly blocks the compensatory synthesis, provides additive benefit).
Ezetimibe's metabolic pathway: absorbed ezetimibe is rapidly glucuronidated (UGT enzymes in enterocytes and hepatocytes) to ezetimibe-glucuronide. The glucuronide is the active form — it preferentially concentrates at the intestinal brush border via enterohepatic cycling. Half-life ~22 hours, protein binding >99%, renal excretion <10%. No CYP450 involvement: ezetimibe is not a substrate, inhibitor, or inducer of CYP3A4, CYP2C8, CYP2C9, or CYP2D6.
Anti-inflammatory mechanisms: ezetimibe suppresses NLRP3 inflammasome activation (reducing IL-1β and IL-18 production), decreases macrophage foam cell formation, and reduces oxidative stress in vascular endothelium. These effects contribute to atherosclerotic plaque stability independently of LDL-C reduction.
Plant sterol selectivity: NPC1L1 also transports phytosterols (plant sterols like sitosterol, campesterol). Ezetimibe blocks phytosterol absorption, making it the only approved therapy for sitosterolemia (a genetic disorder of excessive plant sterol accumulation due to ABCG5/G8 transporter deficiency).
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Simvastatin+ezetimibe reduced primary MACE endpoint from 34.7% to 32.7% (HR 0.936)
Landmark trial. Population is high-risk cardiovascular patients post-ACS, not healthy performance athletes. LDL reduction benefit extrapolates across populations but absolute risk reduction (2%) is specific to this high-risk cohort.
No significant increase in myopathy, rhabdomyolysis, LFT elevation, cancer, or new-onset diabetes vs placebo
Best available safety evidence. Population: general cardiovascular risk patients, not enhanced athletes. Performance athletes may have additional hepatic/muscle baseline stress from AAS use; safety claim applies to general population.
Ezetimibe monotherapy reduces LDL-C 15-20% from baseline
Phan/Dayspring/Toth 2012 review pooled data. Population: general hypercholesterolemic. The 15-20% range applies broadly across sexes, ages, and LDL baselines. Community case data (LDL 131→72 with GLP-1 co-treatment) is consistent.
Ezetimibe suppresses NLRP3 inflammasome and reduces CRP beyond LDL reduction
Omidi et al. 2023 Frontiers review; mechanistic pleiotropic data is not as robust as IMPROVE-IT outcome data. Clinical significance for individual patient outcomes not fully established.
LDL target for AAS users is 70-75 mg/dL; ezetimibe 10mg predicted to reduce LDL from 95 to 70-75 mg/dL in a specific case
Community practitioner-documented individual case from transcript corpus. LDL target below standard guidelines reflects additive inflammatory and cardiovascular risk from AAS use. Not clinical trial data — represents experienced practitioner guidance extrapolated from cardiovascular science.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.